See more : Fathom Nickel Inc. (FNICF) Income Statement Analysis – Financial Results
Complete financial analysis of Eagle Pharmaceuticals, Inc. (EGRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eagle Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- QEM Limited (QEM.AX) Income Statement Analysis – Financial Results
- Porsche Automobil Holding SE (PAH3.DE) Income Statement Analysis – Financial Results
- U City Public Company Limited (U-R.BK) Income Statement Analysis – Financial Results
- Scana ASA (SCANA.OL) Income Statement Analysis – Financial Results
- Investeringsforeningen Investin – K Invest Globale Aktier IV (WEISAK.CO) Income Statement Analysis – Financial Results
Eagle Pharmaceuticals, Inc. (EGRX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.eagleus.com
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 316.61M | 171.55M | 187.80M | 195.89M | 213.31M | 236.71M | 189.48M | 66.23M | 19.10M | 13.68M | 2.54M |
| Cost of Revenue | 94.94M | 42.18M | 45.47M | 60.90M | 61.92M | 57.19M | 55.31M | 15.65M | 11.71M | 7.38M | 3.17M |
| Gross Profit | 221.67M | 129.37M | 142.34M | 135.00M | 151.40M | 179.52M | 134.18M | 50.58M | 7.39M | 6.30M | -627.00K |
| Gross Profit Ratio | 70.01% | 75.41% | 75.79% | 68.91% | 70.97% | 75.84% | 70.81% | 76.37% | 38.67% | 46.04% | -24.69% |
| Research & Development | 34.09M | 51.28M | 30.79M | 36.81M | 44.42M | 32.61M | 30.26M | 27.86M | 16.82M | 9.80M | 12.81M |
| General & Administrative | 98.13M | 66.82M | 75.90M | 73.97M | 57.21M | 73.07M | 37.53M | 15.41M | 5.02M | 0.00 | 0.00 |
| Selling & Marketing | 8.50M | 8.50M | 2.70M | 2.40M | 3.30M | -1.65M | 14.78M | 4.75M | 4.30M | 0.00 | 0.00 |
| SG&A | 106.63M | 75.32M | 78.60M | 76.37M | 60.51M | 71.42M | 52.31M | 20.17M | 9.33M | 4.96M | 6.40M |
| Other Expenses | 0.00 | -6.24M | -8.26M | 700.00K | 52.23M | 35.22M | 32.57M | 0.00 | 35.00K | 3.20K | 12.00K |
| Operating Expenses | 140.71M | 126.60M | 109.38M | 113.18M | 104.93M | 104.02M | 82.58M | 48.02M | 26.14M | 14.75M | 19.20M |
| Cost & Expenses | 235.65M | 168.78M | 154.85M | 174.08M | 166.84M | 161.21M | 137.88M | 63.67M | 37.86M | 22.13M | 22.37M |
| Interest Income | 271.00K | 560.00K | 562.00K | 2.17M | 158.00K | 91.00K | 84.00K | 25.00K | 31.00K | 3.21K | 34.00K |
| Interest Expense | 4.05M | 1.64M | 2.58M | 2.69M | 2.74M | 1.14M | 8.00K | 11.00K | 8.00K | 1.40M | 309.00K |
| Depreciation & Amortization | 12.02M | 4.81M | 4.77M | 4.65M | 3.67M | 3.75M | 1.59M | 112.00K | 104.00K | 134.99K | 240.00K |
| EBITDA | 77.50M | 2.77M | 30.02M | 28.18M | 40.44M | 77.83M | 55.02M | 2.70M | -18.76M | -8.41M | -19.62M |
| EBITDA Ratio | 24.48% | 0.49% | 15.98% | 14.98% | 23.58% | 33.52% | 27.28% | 3.90% | -97.86% | -61.48% | -770.54% |
| Operating Income | 80.96M | -2.91M | 25.25M | 21.82M | 36.62M | 73.99M | 53.35M | 2.56M | -18.76M | -8.46M | -19.83M |
| Operating Income Ratio | 25.57% | -1.70% | 13.45% | 11.14% | 17.17% | 31.26% | 28.16% | 3.87% | -98.21% | -61.81% | -781.06% |
| Total Other Income/Expenses | -19.53M | -7.32M | -10.28M | 183.00K | -2.58M | -1.05M | 76.00K | 14.00K | -515.00K | 1.51M | -333.00K |
| Income Before Tax | 61.43M | -4.55M | 22.68M | 22.00M | 34.04M | 72.95M | 53.43M | 2.57M | -19.27M | -6.95M | -20.16M |
| Income Before Tax Ratio | 19.40% | -2.65% | 12.07% | 11.23% | 15.96% | 30.82% | 28.20% | 3.89% | -100.91% | -50.79% | -794.17% |
| Income Tax Expense | 25.79M | 4.08M | 10.69M | 7.69M | 2.14M | 21.00M | -28.03M | 3.00K | -1.30M | -898.70K | -781.00K |
| Net Income | 35.64M | -8.63M | 11.99M | 14.31M | 31.90M | 51.94M | 81.45M | 2.57M | -17.98M | -6.05M | -19.38M |
| Net Income Ratio | 11.26% | -5.03% | 6.38% | 7.31% | 14.96% | 21.94% | 42.99% | 3.88% | -94.13% | -44.22% | -763.41% |
| EPS | 2.76 | -0.66 | 0.89 | 1.04 | 2.16 | 3.44 | 5.24 | 0.17 | -1.81 | -0.57 | -1.83 |
| EPS Diluted | 2.73 | -0.66 | 0.87 | 1.01 | 2.09 | 3.27 | 4.96 | 0.16 | -1.81 | -0.57 | -1.83 |
| Weighted Avg Shares Out | 12.93M | 13.05M | 13.48M | 13.75M | 14.77M | 15.10M | 15.53M | 15.25M | 9.96M | 10.57M | 10.57M |
| Weighted Avg Shares Out (Dil) | 13.07M | 13.05M | 13.77M | 14.14M | 15.28M | 15.91M | 16.43M | 16.25M | 9.96M | 10.57M | 10.57M |
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration
INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Eagle Pharmaceuticals, Inc. On Behalf of Shareholders
Union Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals Shares
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
Shareholders of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX
EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options
Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX
Source: https://incomestatements.info
Category: Stock Reports